Noxopharm (ASX: NOX) — Company Overview, News & Financial Data
Noxopharm is a clinical-stage biotechnology company focused on discovering and developing treatments for cancer and inflammatory diseases.
Noxopharm
Noxopharm is a clinical-stage biotechnology company focused on discovering and developing treatments for cancer and inflammatory diseases. The company leverages proprietary platform technologies to address unmet medical needs across oncology, autoimmunity, and mRNA medicine enhancement. Its primary drug candidate pipeline includes the Sofra platform, which focuses on oligonucleotide-based therapies for autoimmune and inflammatory conditions, and the Chroma platform, directed toward novel small-molecule treatments for cancer. Additionally, the company is advancing clinical and preclinical research in therapeutic areas including lupus, inflammation, and mRNA vaccine safety.
Snapshot
Operations
Products and/or services of Noxopharm
- Oligonucleotide Technology Platform: Proprietary platform utilizing short nucleic acid molecules to modulate immune system activity and selectively silence disease-causing targets. Research activities center on developing synthetic RNA and DNA constructs for inflammatory disorders, mRNA vaccine modulation, and targeted cancer immunotherapies.
- Small Molecule Oncology Platform: Preclinical research program centered on chroman-derived chemical compounds designed to inhibit key cellular targets in tumor microenvironments. The pipeline targets multiple cancer indications by disrupting metabolic pathways and enhancing sensitivity to standard cytotoxic chemotherapies or immune system agents.
- Phase 1 Immuno-Oncology Therapeutics: Clinical-stage drug candidate evaluating dual action radiosensitizer and immunomodulatory properties in investigator-initiated Phase 1 trials. Clinical evaluation focuses on combining targeted small molecules with external radiation or immune checkpoint inhibitors in patients with advanced solid tumors.
- mRNA Vaccine Safety Therapeutics: Specialized oligonucleotide development aimed at controlling inflammation and unwanted immune activation associated with synthetic mRNA therapies. The program engineers custom RNA sequences to suppress off-target innate immune reactions while maintaining effective antigen translation efficiency.
- Autoimmune Disease Programs: Therapeutic research focused on chronic inflammatory conditions including cutaneous lupus erythematosus. Candidate development involves short nucleic acid sequences designed to downregulate hyperactive toll-like receptor signaling and limit localized tissue inflammation in preclinical and early clinical studies.
- RNA Drug Discovery Infrastructure: Specialized biotechnology laboratories based in Australia dedicated to nucleic acid synthesis, molecular biology screening, and early-stage formulation development. Operations combine internal research capabilities with academic collaborative networks to accelerate pipeline maturation toward human clinical testing.
Noxopharm executive team
- Dr. Gisela MautnerCEO, Executive MD & Director
- Mr. Shawn Van Boheemen FCPA, J.P.Chief Financial Officer
- Ms. Jeanette Bell Ph.D.Chief Operating Officer
- Dr. Olivier Laczka B.S., M.Sc., Ph.D.Chief Scientific Officer of Inflammation
- Mr. David James Franks BEc, C.A., F Fin, J.P.Company Secretary